По данным ВОЗ, астма является сегодня одним из самых распространенных заболеваний в мире, охватив свыше 300 млн человек, и ее распространенность продолжает расти, особенно в развивающихся странах. Астма является сложным заболеванием, которое включает множество вариантов течения. В настоящее время очень большой интерес и дискуссию вызывает фенотипирование астмы.
Walker C et aL. Allergic and nonallelic asthmatics have distinct patterns of T-ceLL activation and cytokine production in peripheral blood and bronchoaLveoLar lavage. Am Rev Respir Dis. 1992, 146: 109-115.
WaLker C et aL. T ceLL subsets and their soluble products regulate eosinophiLia in aLLergic and non-aLLergic asthma. J Immunol. 1991, 146: 1829-1835.
Duan OL et aL. ReguLatory hapLotypes in ARGI are associated with aLtered bronchodiLator response. Am J Respir Crit Care Med. 2011, 183: 449-454.
Virchow JC et aL. T ceLLs and cytokines in bronchoaLveoLar Lavage fLuid after segmentaL aLLergen provocation in atopic asthma. Am J Respir Crit Care Med. 1995, 151: 960-968.
Knudsen TB et aL. A popuLation-based cLinicaL study of aLLergic and non-aLLergic asthma. J.Asthma, 2009, 46: 91-94.
Gibson PG. InfLammatory phenotypes in aduLt asthma: cLinicaL appLications. Clin Respir J, 2009, 3: 198-206.
Chiesi Pharmaceutici SpA. ModuLite®: the vaLue of Chiesi_s technoLgy in the treatment of asthma and COPD (onLine). AvaiLabLe from URL: hppt//www.chiesigroup.com (Accessed 2006 May 25).hppt//www.chiesigroup.com
Thongngarm T, SiLkoff PE, Kossack WS, NeLson HS. HydrofLuoroaLkane 134A becLomethasone or chLorofLuorocarbon fLuticasone: effect on smaLL airways in poorLy controLLed asthma. J.Asthma, 2005, 42: 257-263.
GoLdin JG, Tashkin DP, KLeerup EC et aL. Comparative effects of hydrofLuoroaLkane and chLorofLuorocarbon becLometha-sone dipropionate inhaLation on smaLL airways: assessment with functionaL heLicaL thin section computed tomography. J. Allergy Clin. Immunol. 1999, 104: 258-267.
Ohbayashi H. One year evaLuation of the preventative effect of hydrofLuoroaLkane becLomethasone dipropionate on eosinophiLic infLammation of asthmatic peripheraL airways. Respiration 2007, 74: 146-153.
Van Schayck CP, DonneLL D. The efficacy and safety of OVAR (hydrofLuoroaLkane becLometasone diproprionate extrafine aerosoL) in asthma (part 1): an update of cLinicaL experience in aduLts. Int. J. Clin. Pract. 2004, 58: 678-688.
Bonnet Gonod F, Kottakis I, BaLLabio M et aL. Superior efficacy of a Low daiLy dose of a new fixed combination of becLometasone dipropionate/formoteroL pMDI compared to an increased daiLy dose of BDP in moderate persistent asthma: a 3 month cLinicaL study. 16th Annual Congress of the European Respiratory Society, 2006, Sep. 2-6, Munich: 1237.
Huchon G, Magnussen H, ChuchaLin A et aL. Lung function and asthma controL with becLomethasone and formoteroL in a singLe inhaLer. Respir. Med. 2009, 103: 41-49.